Product Name: Factor XIIIa Antibody [SPM180]
Species Reactivity: Human
Tested Applications: ELISA, Flow, IF, IHC-P, WB
Applications: ELISA: 2-4 ug/ml; order the BSA-free formulation for coatingIF: 1-2 ug/mlFlow Cytometry: 0.5-1 ug/million cells in 0.1mlWB: 0.5-1 ug/mlIHC (FFPE): 1-2 ug/ml for 30 min at RTTitering of the Factor XIIIa antibody may be required for optimal performance.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: A human partial recombinant protein corresponding to amino acids 46-181 was used as the immunogen for the Factor XIIIa antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1009820-21-6
CX-4945
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: F13A1, coagulation factor XIII, A1 polypeptide, RP11-232H4.1, F13A, Coagulation factor XIII A chain, Coagulation factor XIII, A polypeptide, TGase, bA525O21.1 (coagulation factor XIII, A1 polypeptide), coagulation factor XIII A1 subunit, factor XIIIa
Accession NO.:
Protein Ino:
Official Symbol: F13A1
Geneid: 2162
Background: Factor XIIIa has been identified in platelets, megakaryocytes, and fibroblast-like mesenchymal or histiocytic cells in the placenta, uterus, and prostate, monocytes and macrophages and dermal dendritic cells. Anti-Factor XIIIa has been found to be useful in differentiating between dermatofibroma (almost all cases are positive), dermatofibrosarcoma protuberans (-/+) and desmoplastic malignant melanoma (-). Anti-Factor XIIIa positivity is also seen in capillary hemagioblastoma, hemangioendothelioma, hemangiopericytoma, xanthogranuloma, xanthoma, hepatocellular carcinoma, glomus tumor, and meningioma.
PubMed ID:http://aac.asm.org/content/40/6/1387.abstract
